Aurinia Published P-III Extension Study (AURORA 2) Results of Lupkynis (voclosporin) for Lupus Nephritis in Arthritis & Rheumatology
Shots:
- The P-III extension study evaluating Lupkynis vs PBO in combination with mycophenolate mofetil (target dose of 2g/day) & low-dose glucocorticoids (target dose of ≤2.5mg/day) in adult patients with active LN who completed 1yr. of treatment in the P-III trial (AURORA 1)
- The results showed that Voclosporin was well tolerated with no new or worsening safety signals & clinical efficacy over 3yrs. of treatment was maintained as observed by the maintenance of UPCR reductions, sustained CRR, and preserved kidney function which suggested a positive benefit-risk profile in LN patients
- At 12mos., CRR was reported in 52.6% vs 34.0% while 50.9% vs 39.0% at 36mos., low rates of serious infections in both groups (12.9% vs 17.0%)
Ref: Aurinia | Image: Aurinia
Related News:- Otsuka’s Lupkynis (voclosporin) Receives NICE Recommendation for the Treatment of Active Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
